Stemline Therapeutics Announces Proposed Public Offering of Common Stock

NEXT STORY
New England Journal of Medicine Publishes Results from Pivotal Study of WAYLIVRA® (volanesorsen) in Patients with Familial Chylomicronemia Syndrome
PREV STORY
CytomX Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Argos Therapeutics to Report Third Quarter 2017 Financial Results and Operational Highlights on Thursday, November 9, 2017

DURHAM, N.C., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (NASDAQ:ARGS), an immuno-oncology ...

author_avatar
NASDAQ Market News

Jounce Therapeutics Initiates Phase 2 Portion of ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors

CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage ...

author_avatar
NASDAQ Market News

Spark Therapeutics to Participate in Multiple Conferences in September

PHILADELPHIA, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene ...

author_avatar
NASDAQ Market News